3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase 1
5
Phase 1/2
2
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
7
Breast Neoplasms
6
Colorectal Neoplasms
4
Ovarian Neoplasms
3
Neuroblastoma
3
Neoplasm Metastasis
3
Uveal Melanoma
2
Unspecified Adult Solid Tumor, Protocol Specific
2
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Lung Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms, Male
2
Adenocarcinoma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Interventions
pembrolizumab
37
Carboplatin
26
Radiotherapy
23
Cisplatin
19
Paclitaxel
18
Erlotinib Hydrochloride
18
Docetaxel
15
Gemcitabine
14
Pemetrexed
13
Etoposide
12
osimertinib
11
Nivolumab
11
durvalumab
9
atezolizumab
9
Radiosurgery
8
Magnetic Resonance Spectroscopy
8
Cetuximab
7
Specimen Handling
6
Cyclophosphamide
6
130-nm albumin-bound paclitaxel
6
Taxes
5
Immunoglobulin G
5
Gefitinib
5
Biopsy
5
Bevacizumab
5
fludarabine
4
Radiation
4
Ipilimumab
4
Disulfides
4
Albumin-Bound Paclitaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lung Neoplasms
×
sargramostim
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled
NCT01789099
2024-12-16
UV1-hTERT2012L
Ultimovacs ASA
Phase 1/2
Completed
18 enrolled